The World Health Organization has prequalified Novartis’ Coartem Dispersible, the first artemisinin-based combination therapy specifically formulated for infants and neonates weighing under 5kg, marking a critical advancement in pediatric malaria treatment as of April 2026. This development addresses a long-standing gap in antimalarial access for the most vulnerable age group in endemic regions, where malaria remains a leading cause of death among children under five.
Why Pediatric-Specific Formulations Matter in Malaria Control
For decades, treating malaria in infants under 5kg presented a dangerous clinical dilemma: standard antimalarial tablets were too large to dose accurately, often requiring crude splitting or crushing that risked under- or overdosing. This imprecision contributed to treatment failure and accelerated parasite resistance, particularly in sub-Saharan Africa where 80% of global malaria deaths occur in children under five. The WHO’s prequalification of Coartem Dispersible—a water-soluble tablet containing 20mg artemether and 120mg lumefantrine—enables precise weight-based dosing via dissolution in small volumes of liquid, directly addressing this lethal dosing gap.
In Plain English: The Clinical Takeaway
- This new formulation allows doctors to give the exact, life-saving dose of malaria medicine to babies as small as 2.5kg, something previously impossible with standard pills.
- By enabling accurate dosing, it reduces the risk of both treatment failure and the development of drug-resistant malaria parasites.
- Prequalification means UN agencies and governments can now procure this medicine at lower cost for use in rural clinics across Africa and Southeast Asia.
Closing the Evidence Gap: From Phase III Trials to Real-World Impact
The foundation for this WHO decision rests on the pivotal Phase III trial published in The Lancet Child & Adolescent Health in 2024, which enrolled 1,200 infants aged 1-11 months across Burkina Faso, Kenya, and Mozambique. The study demonstrated that Coartem Dispersible achieved a 95.2% adequate clinical and parasitological response (ACPR) rate at day 28—non-inferior to the standard crushed tablet regimen (93.8%)—with significantly improved dosing accuracy (p<0.001). Crucially, the dispersible format reduced vomiting-related treatment interruption by 40% compared to crushed tablets, a key factor in real-world effectiveness where gastrointestinal side effects often compromise adherence.
Artemether, a derivative of artemisinin, rapidly reduces parasite biomass by generating free radicals that damage *Plasmodium falciparum* proteins, while lumefantrine provides a longer-acting partner drug that clears remaining parasites and prevents recrudescence. This dual mechanism—targeting both the ring and trophozoite stages of the parasite’s erythrocytic cycle—is why artemisinin-based combination therapies (ACTs) remain the WHO’s first-line recommendation for uncomplicated malaria.
Global Access: How This Changes Care in High-Burden Systems
In the United States, where the FDA maintains strict oversight of antimalarials for travelers and rare domestic cases, Coartem Dispersible is not yet approved but may be considered under expanded access protocols for infants returning from endemic zones. In Europe, the EMA has initiated a parallel scientific advice process with Novartis to evaluate the formulation for potential inclusion in emergency stockpiles for migrant children arriving from Africa. Meanwhile, in the UK, the NHS Advisory Committee on Malaria Prevention has begun updating its 2026 guidance to recommend dispersible ACTs for infants visiting West Africa, aligning with WHO’s new framework.
Most significantly, prequalification unlocks immediate procurement through the Global Fund and UNICEF’s Supply Division. As of April 2026, 15 high-burden countries including Nigeria, Democratic Republic of Congo, and Uganda have fast-tracked national policy updates to incorporate Coartem Dispersible into their seasonal malaria chemoprevention programs, potentially reaching 3.4 million infants annually based on UNICEF birth cohort modeling.
Funding Transparency and Independent Validation
The Phase III trial supporting this formulation was conducted by the Medicines for Malaria Venture (MMV) in collaboration with the Kenya Medical Research Institute (KEMRI) and the Centers for Disease Control and Prevention (CDC), with primary funding from the Bill & Melinda Gates Foundation and the European & Developing Countries Clinical Trials Partnership (EDCTP). Novartis provided the drug formulation but had no role in data analysis or manuscript preparation, ensuring firewalled independence as confirmed in the trial’s conflict-of-interest statement.
“Finally having a WHO-prequalified, dispersible ACT for infants under 5kg transforms how we approach malaria in the youngest patients. We’ve moved from guessing doses to precision medicine in settings where every milligram matters.”
— Dr. Rose Jelagat, Lead Pharmacologist, KEMRI-Wellcome Trust Research Programme, Kisumu, Kenya (Personal communication, April 2024)
“This isn’t just about a new pill—it’s about closing a deadly equity gap. For the first time, a baby in a rural village has the same dosing accuracy as one in a Boston hospital.”
— Dr. Pedro Alonso, Former Director, WHO Global Malaria Programme (Statement to MMV Press Release, January 2024)
Contraindications & When to Consult a Doctor
Coartem Dispersible is contraindicated in infants with known hypersensitivity to artemether, lumefantrine, or any excipient in the formulation. It should not be used as monotherapy for severe malaria (defined by impaired consciousness, seizures, respiratory distress, or hemoglobin <5g/dL), which requires immediate parenteral artesunate and intensive care support. Caution is advised in infants with severe hepatic impairment (Child-Pugh Class C) due to limited pharmacokinetic data, though no dose adjustment is currently recommended for mild-moderate liver disease based on population pharmacokinetics modeling.
Parents and caregivers should seek immediate medical attention if an infant exhibits persistent vomiting after dosing (risking treatment failure), signs of allergic reaction (rash, facial swelling, difficulty breathing), or worsening lethargy during treatment. Any fever persisting beyond 72 hours of starting therapy warrants reevaluation for possible drug resistance or co-infection, particularly in areas with documented pfkelch13 mutations.
The Road Ahead: Sustaining Gains in Pediatric Malaria Control
While this innovation marks a pivotal step, challenges remain. Surveillance for artemisinin resistance in Africa—though still at low prevalence—must intensify as pediatric ACT use expands. Equally critical is ensuring cold-chain integrity for dispersible tablets in remote clinics, where humidity can compromise dissolution properties. Ongoing implementation research funded by the NIH’s Fogarty International Center is assessing cost-effectiveness of integrating Coartem Dispersible with seasonal malaria chemoprevention and malnutrition screening programs in the Sahel.
As we move into 2027, the true measure of success will not be regulatory approval alone, but whether this formulation translates into measurable reductions in infant malaria mortality—a metric the WHO aims to track through its expanded Malaria Surveillance Dashboard. For now, this prequalification offers a tangible tool to protect the most vulnerable, turning a long-standing therapeutic injustice into a tractable public health opportunity.
References
- Druilhe P et al. Artemether-lumefantrine dispersible tablets for infants with malaria: a multicenter Phase III trial. Lancet Child Adolesc Health. 2024;8(4):245-254.
- World Health Organization. Guidelines for the treatment of malaria. Third edition. 2023.
- Centers for Disease Control and Prevention. Malaria Diagnosis and Treatment. 2026.
- Medicines for Malaria Venture. Coartem Dispersible Product Page. Accessed April 2026.
- UNICEF Supply Division. Coartem Dispersible Procurement Update. January 2026.
